Proven leadership in cardiovascular, metabolic disease and dermatology trials





News & Information » Press Releases

MEDIA INQUIRIES

Media inquiries about Integrium Clinical Research or its services should be directed to:

                   Randy Wambold                              Juli Greenwood
Tel +1 (781) 672-3119 Tel +1 (781) 672-3137
rwambold@chenpr.com jgreenwood@chenpr.com

# # #

American Diabetes Association Names Integrium Clinical Research 2011 Honoree

Hamilton, New Jersey — November 5, 2011 – The American Diabetes Association is honoring Integrium Clinical Research at its 16th annual gala on November 5 at the Grounds for Sculpture in Hamilton, New Jersey. The gala not only recognizes leaders and pioneering researchers in diabetes but also aims to raise funds needed to expand and continue outreach programs in New Jersey.

Integrium is a contract research organization (CRO) with a therapeutic focus on cardiovascular and metabolic diseases. Executive Director of the American Diabetes Association in New Jersey, Mathieu N. Nelessen says Integrium earned this honor for its successful efforts to speed the development of new and more effective drug treatment for diabetes.

Integrium has conducted 18 clinical trials of treatment for diabetes at 557 study sites. In addition to trials targeting diabetes, Integrium has conducted more than 100 cardiovascular and renal disease trials, which have an impact on diabetes care since diabetes is a leading cause of kidney failure and more than two-thirds of people with diabetes die of heart disease or stroke.

Integrium founder Dr. David H. G. Smith observes that the diabetes epidemic is not abating. “A staggering 366 million people worldwide suffer from diabetes. One in ten American adults has diabetes and that number may triple in the coming decades. The disease is the seventh leading cause of death in the U.S. More than half a million people in New Jersey have been diagnosed with diabetes and an estimated 200,000 have diabetes but have not yet been diagnosed.”

About Diabetes

The United States is in the throes of a diabetes epidemic. An estimated 24 million children and adults have diabetes. Another 57 million others have pre-diabetes, elevated blood glucose levels that increase their risk of developing diabetes, heart disease and stroke.

Diabetes is a leading cause of kidney failure, blindness, amputations and pregnancy complications and is the seventh leading cause of death in the U.S. timely diagnosis and effective treatment help to prevent and reduce the symptoms and life-threatening complications of diabetes.

About the American Diabetes Association

The American Diabetes Association funds research to prevent, cure and manage diabetes; deliver services to hundreds of communities; provide objective and credible information and; is the voice for persons denied their rights because of diabetes.

About Integrium, LLC
Integrium is a full-service clinical research organization (CRO) designing, conducting, and analyzing clinical trials for pharmaceutical research in dermatology, cardiovascular, and metabolic disorders. It is committed to focused, specialized, and long-term personalized service to its partners. It has a strong reputation for delivering high-quality management of clinical development programs. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.

  

# # #

Tustin, Calif. — December 16, 2010 – A higher than usual blood pressure reading at the doctor’s office does not necessarily mean that a patient suffers from hypertension.

# # #

Tustin, Calif. – December 6, 2010 – In its 12 year history, cardiovascular, dermatology and metabolic CRO Integrium has developed and managed over 150 successful clinical trials for clients, consistently beating patient enrollment goals and reducing costs.

# # #

Tustin, Calif. – November 22, 2010 – November is American Diabetes Month and Integrium LLC, a Contract Research Organization (CRO) with a therapeutic focus on cardiovascular and metabolic diseases, is at the forefront of clinical research to improve diabetes treatment.

# # #

Tustin, Calif. – Marketwire - October 13, 2010 – Integrium LLC, a Contract Research Organization (CRO) specializing in cardiovascular and metabolic disease clinical research, today announced that its Director of Project Management and Field Operations Liza Moore will participate in MAGI's Clinical Research Conference West to be held October 24-27 at The Fairmont San Francisco. Ms. Moore will moderate a discussion titled "Just CROs: Challenges and Solutions".

# # #

Tustin, Calif. – September 14, 2010 – Integrium LLC, a Contract Research Organization (CRO) specializing in cardiovascular and metabolic disease clinical research, today announced recent success with two of its leading biopharmaceutical customers, Graceway® Pharmaceuticals, LLC and Resverlogix Corp. (TSX: RVX). Integrium helped both companies tighten patient enrollment timelines to dramatically reduce study spend.

# # #

# # #

Tustin, Calif. – June 8, 2010 – Integrium LLC, a contract research organization (CRO) specializing in cardiovascular and metabolic disease clinical research, today announced its expansion into the dermatology therapeutic area. Dr. Mary Spellman, dermatology drug development expert, will lead Integrium’s dedicated Dermatology Clinical Research Group ...>>

# # #

April 13, 2010 - As reported last week, full-service CRO Integrium, a specialist in running trials for dermatology, cardiovascular and metabolic disease treatments, has signed with Phase Forward for the latter's Interactive Response Technology (IRT) trial planning and management solution. Integrium became a Phase Forward customer about a year ago, when it implemented the InForm EDC solution ...>>

# # #

WALTHAM, Mass. – April 6, 2010 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Integrium LLC, a contract research organization (CRO) specializing in dermatology, cardiovascular and metabolic disease clinical research, recently signed an agreement for the use of Phase Forward™ IRT ...>>

# # #

PHILADELPHIA, January 30, 2009 -- eResearchTechnology, Inc. (ERT), (NASDAQ: ERES - News), and Integrium, LLC announced today their alliance to provide integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring centralized core laboratory services to clinical trial sponsors and managers worldwide ...>>

# # #